# China NMPA Drug Inspection - Qingyang Yixiang Pharmaceutical Co., Ltd. - Plantain

Source: https://www.keypedia.com/records/china_drug_inspection/qingyang-yixiang-pharmaceutical-co-ltd/df6293b2-fd15-48b0-8b2e-57d9c47b04eb
Source feed: China

> China NMPA drug inspection for Qingyang Yixiang Pharmaceutical Co., Ltd. published April 29, 2022. Drug: Plantain. The Gansu Provincial Drug Administration released an announcement on April 29, 2022, regarding the results of its second

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: Qingyang Yixiang Pharmaceutical Co., Ltd.
- Publication Date: 2022-04-29
- Drug Name: Plantain
- Inspection Finding: Non-compliant with standard requirements
- Action Taken: Drug regulatory authorities have required relevant entities to take risk control measures and investigate and punish substandard products in accordance with relevant laws and regulations.
- Summary: The Gansu Provincial Drug Administration released an announcement on April 29, 2022, regarding the results of its second phase of drug sampling inspections for the year. Following testing performed by the Tianshui Municipal Drug Inspection and Testing Center, a batch of the prepared herbal medicine Plantago asiatica was found to be substandard. The sample in question was obtained from Tianshui Kaiyuan Pharmaceutical Co., Ltd. and was labeled as manufactured by Qingyang Yixiang Pharmaceutical Co., Ltd. Under the regulatory framework of the National Medical Products Administration (NMPA) and provincial pharmaceutical oversight, the inspection identified that the product failed to meet established quality standards. In response to these violations, the regulatory body has instructed the involved entities to implement immediate risk control measures. Additionally, the authorities are required to manage the disposal of the substandard products and proceed with enforcement actions as dictated by relevant laws and regulations. This notice underscores the ongoing efforts by regional administrators to ensure the integrity of herbal medicines and protect public health through rigorous sampling and transparent reporting of non-compliance.

Company: https://www.keypedia.com/companies/qingyang-yixiang-pharmaceutical-co-ltd/e1242a79-d7e5-488e-aba8-0542e77866aa